2. Membrane Transporter/Ion Channel
  3. Chloride Channel Potassium Channel
  4. DCPIB

DCPIB est un inhibiteur des canaux anioniques à volume régulé (VRAC) qui est sélectif, réversible et puissant. DCPIB active en fonction de la tension les canaux potassiques TREK1 et TRAAK et inhibe TRESK, TASK1 et TASK3 (IC50s de 0,14, 0,95, 50,72 μM, respectivement). DCPIB est également un bloqueur sélectif du courant de chlorure induit par le gonflement (ICl, gonflement), avec un IC50 de 4,1 μM dans les cellules CPAE.

DCPIB is a selective, reversible and potent inhibitor of volume-regulated anion channels (VRAC). DCPIB voltage-dependently activates potassium channels TREK1 and TRAAK, and inhibits TRESK, TASK1 and TASK3 (IC50s: 0.14, 0.95, 50.72 μM, respectively). DCPIB is also a selective blocker of swelling-induced chloride current (ICl,swell), with an IC50 of 4.1 μM. DCPIB is a useful tool for investigating structure-function studies of K2P channels.

For research use only. We do not sell to patients.

DCPIB Chemical Structure

DCPIB Chemical Structure

CAS No. : 82749-70-0

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 95 In-stock
Solution
10 mM * 1 mL in DMSO USD 95 In-stock
Solid
5 mg USD 86 In-stock
10 mg USD 143 In-stock
50 mg USD 605 In-stock
100 mg USD 768 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

DCPIB Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

DCPIB is a selective, reversible and potent inhibitor of volume-regulated anion channels (VRAC). DCPIB voltage-dependently activates potassium channels TREK1 and TRAAK, and inhibits TRESK, TASK1 and TASK3 (IC50s: 0.14, 0.95, 50.72 μM, respectively). DCPIB is also a selective blocker of swelling-induced chloride current (ICl,swell), with an IC50 of 4.1 μM. DCPIB is a useful tool for investigating structure-function studies of K2P channels[1][2].

IC50 & Target

IC50：0.14 μM (TRESK), 0.95 μM (TASK1), 50.72 μM (TASK3)[1], 4.1 μM (ICl,swell, CPAE cells)[2]
In Vitro

DCPIB (10 μM) activates TREK1 and enhances TRAAK currents in COS-7 cells[1].
? DCPIB (10 μM) prominently and reversibly suppresses TRESK currents in COS-7 cells, with an IC50 of 0.14 μM[1].
? DCPIB (10?μM) displays selectivity for ICl,swell and has no significant inhibitory effects on ICl,Ca in CPAE cells[2].
? DCPIB (10?μM, 5 min) has no effect on attenuate subsequent swelling in cardiomyocytes[2].
? DCPIB (10 μM, 3 h) inhibits LPS-induced MAPK activation in BV2 cells[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

DCPIB Related Antibodies

Immunofluorescence[3]

Cell Line: BV2 cells
Concentration: 10 μM
Incubation Time: 3 h
Result: Significantly decreased Ki67 positive staining microglia and pro-inflammatory cytokine (TNF-α, IL-1β) secretion.

Western Blot Analysis[3]

Cell Line: BV2 cells
Concentration: 10 μM
Incubation Time: 3 h
Result: Inhibited migratory potential of transient OGD (Oxygen-glucose deprivation) exposed BV2 cells.
In Vivo

LDN-212854 (intracerebroventricular infusion, 1 mM, 10 μL) suppresses microglial activation and ameliorates neuronal damage in rMCAO rats[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Reversible middle cerebral artery occlusion (rMCAO) model[3]
Dosage: 1 mM, 10 μL
Administration: Administered manually for 20s by intracerebroventricular infusion
Result: Diminished Pyramidal neurons injury induced by rMCAO in the CA1 region.
Molecular Weight

427.36

Formula

C22H28Cl2O4
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C(O)CCCOC1=CC2=C(C(C(C3CCCC3)(CCCC)C2)=O)C(Cl)=C1Cl
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (233.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.3399 mL 11.6997 mL 23.3995 mL
5 mM 0.4680 mL 2.3399 mL 4.6799 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (4.87 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.08 mg/mL (4.87 mM); Clear solution; Need ultrasonic

    This protocol yields a clear solution of 2.08 mg/mL.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.93%

COA (248 KB) HNMR (231 KB) LCMS (280 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.3399 mL 11.6997 mL 23.3995 mL 58.4987 mL
5 mM 0.4680 mL 2.3399 mL 4.6799 mL 11.6997 mL
10 mM 0.2340 mL 1.1700 mL 2.3399 mL 5.8499 mL
15 mM 0.1560 mL 0.7800 mL 1.5600 mL 3.8999 mL
20 mM 0.1170 mL 0.5850 mL 1.1700 mL 2.9249 mL
25 mM 0.0936 mL 0.4680 mL 0.9360 mL 2.3399 mL
30 mM 0.0780 mL 0.3900 mL 0.7800 mL 1.9500 mL
40 mM 0.0585 mL 0.2925 mL 0.5850 mL 1.4625 mL
50 mM 0.0468 mL 0.2340 mL 0.4680 mL 1.1700 mL
60 mM 0.0390 mL 0.1950 mL 0.3900 mL 0.9750 mL
80 mM 0.0292 mL 0.1462 mL 0.2925 mL 0.7312 mL
100 mM 0.0234 mL 0.1170 mL 0.2340 mL 0.5850 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

DCPIB Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

DCPIB82749-70-0Chloride ChannelPotassium ChannelCl− Channels KcsACOS-7CPAE cellswellingcardiomyocytesischemiarMCAOInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
DCPIB
Cat. No.:
HY-103371
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.